| NCT ID | Title | Status | Phases | Start Date | Completion Date | Primary Completion Date |
|---|---|---|---|---|---|---|
| NCT05984199 | Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant | TERMINATED | PHASE1, PHASE2 | 2023-12-11 | 2025-05-28 | 2025-05-28 |
| NCT04849910 | Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS | TERMINATED | PHASE1, PHASE2 | 2021-12-16 | 2025-05-28 | 2025-05-28 |